GlassScriptPhysician profile
Bryan Walter Laue
NPI 1427027333
$2,681.43
in general payments reported to CMS, 2019-2025
22 companies · $641 in 2025
The $641 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $72.17 · 2021: $198 · 2022: $462 · 2023: $427 · 2024: $651 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $888.96 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $267.37 | 2021-2025 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $237.57 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $227.87 | 2019-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $187.44 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.60 | 2019-2022 | |
| Pfizer INC. | $137.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $123.31 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $81.71 | 2020-2024 | Dyanavel Xr |
| Alk-Abello, INC | $67.24 | 2022-2025 | Neffy, Grastek, Odactra |
| Neos Therapeutics, LP | $56.98 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $51.52 | 2023 | |
| Genentech USA, INC. | $34.47 | 2021-2023 | Xofluza |
| Abbvie INC. | $30.73 | 2020-2022 | |
| Adlon Therapeutics L.P. | $25.60 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $20.14 | 2025 | Neffy |
| Biogen, INC. | $19.50 | 2022 | |
| Abbott Laboratories | $19.10 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.46 | 2025 | Zoryve |
| Shire North American Group INC | $16.63 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.34 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Laue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.